Categories Earnings, Health Care

ACADIA Pharmaceuticals (ACAD): Q3 2019 Earnings Snapshot

— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q3 2019 loss of $0.29 per share, vs. $0.40 expected.

— Revenues grew 62% to $94.6 million, vs. $88.4 million expected.

— Research and development expenses were $62.6 million, compared to $53.1 million last year.

— FY19 NUPLAZID net sales guidance is increased to $330 million to $340 million from the previous range of $320 million to $330 million.

— ACAD shares fell 0.81% following the announcement.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Docusign (DOCU) Earnings: 4Q25 Key Numbers

Docusign, Inc. (NASDAQ: DOCU) reported total revenue of $776.3 million for the fourth quarter of 2025, up 9% year-over-year. Net income was $83.5 million, or $0.39 per share, compared to

DG Q4 Call Highlights: Consumer Shifts, Inventory Wins, and Rural Delivery Boom!

Dollar General Corp., a retailer that operates discount stores, in its Q4 earnings call discussed Dollar General's financial strategy to reach 6-7% operating margins by 2028 through shrink reduction, inventory

ULTA Earnings: Highlights of Ulta Beauty’s Q4 2024 results

Ulta Beauty, Inc. (NASDAQ: ULTA), a leading retailer of cosmetics and personal care products, on Thursday reported a decrease in net sales for the fourth quarter of 2024. Fourth-quarter net

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close